PMID- 33191380
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 0021-4884 (Print)
IS  - 0021-4884 (Linking)
VI  - 69
IP  - 9
DP  - 2020
TI  - [EFFICACY, SAFETY AND IMMUNOLOGICAL RESPONSE WITH SQ HOUSE DUST MITE SUBLINGUAL 
      IMMUNOTHERAPY-TABLET BY BODY WEIGHT IN CHILDREN].
PG  - 918-927
LID - 10.15036/arerugi.69.918 [doi]
AB  - BACKGROUND: Sublingual immunotherapy-tablet (SLIT-tablet) treatment includes the 
      same dose regardless of the patients' age or body weight. We investigated the 
      efficacy, safety and immunological response of SQ house dust mite (HDM) 
      SLIT-tablet treatment in relation to body weight in children. METHODS: Total 
      combined rhinitis score (TCRS), adverse events (AEs), adverse drug reactions 
      (ADRs) and immunological response (IgE, IgG4) were evaluated post hoc in three 
      subgroups (body weight < 30kg, 30-44kg, >/= 45kg) of patients from a clinical trial 
      for Japanese children with HDM allergic rhinitis (JapicCTI-152953). RESULTS: No 
      apparent differences in TCRS were observed between the three subgroups. No 
      differences in the frequency or nature of AEs were detected between the subgroups 
      but the incidence of ADRs was decreased in the lower body weight subgroup. The 
      most common ADRs occurred locally in the oral cavity and were categorized as 
      mild. The levels of HDM specific IgE and IgG4 were increased compared to baseline 
      in all subgroups. CONCLUSION: There were no influences of body weight for 
      efficacy, safety, and immunological response in treatment with SQ HDM 
      SLIT-tablet. These results indicated that SLIT dosage in children is same as 
      adults without any concern in safety.
FAU - Sato, Sakura
AU  - Sato S
AD  - Department of Allergy, Clinical Research Center for Allergy and Rheumatology, 
      National Hospital Organization Sagamihara National Hospital.
FAU - Hata, Hiroki
AU  - Hata H
AD  - Torii Pharmaceutical Co., Ltd.
FAU - Kobayashi, Satoko
AU  - Kobayashi S
AD  - Torii Pharmaceutical Co., Ltd.
FAU - Asaumi, Tomoyuki
AU  - Asaumi T
AD  - Department of Allergy, Clinical Research Center for Allergy and Rheumatology, 
      National Hospital Organization Sagamihara National Hospital.
FAU - Yanagida, Noriyuki
AU  - Yanagida N
AD  - Department of Allergy, Clinical Research Center for Allergy and Rheumatology, 
      National Hospital Organization Sagamihara National Hospital.
FAU - Azuma, Ryuji
AU  - Azuma R
AD  - Torii Pharmaceutical Co., Ltd.
FAU - Ohashi-Doi, Katsuyo
AU  - Ohashi-Doi K
AD  - Torii Pharmaceutical Co., Ltd.
FAU - Ebisawa, Motohiro
AU  - Ebisawa M
AD  - Department of Allergy, Clinical Research Center for Allergy and Rheumatology, 
      National Hospital Organization Sagamihara National Hospital.
LA  - jpn
PT  - Clinical Trial
PT  - Journal Article
PL  - Japan
TA  - Arerugi
JT  - Arerugi = [Allergy]
JID - 0241212
RN  - 0 (Allergens)
RN  - 0 (Antigens, Dermatophagoides)
RN  - 0 (Tablets)
SB  - IM
MH  - Allergens
MH  - Animals
MH  - Antigens, Dermatophagoides/*administration & dosage
MH  - *Body Weight
MH  - Child
MH  - Humans
MH  - Pyroglyphidae/immunology
MH  - *Rhinitis, Allergic/therapy
MH  - *Sublingual Immunotherapy
MH  - Tablets
MH  - Treatment Outcome
OTO - NOTNLM
OT  - children
OT  - efficacy
OT  - immunological response
OT  - safety
OT  - sublingual immunotherapy
EDAT- 2020/11/17 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/11/16 05:57
PHST- 2020/11/16 05:57 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.15036/arerugi.69.918 [doi]
PST - ppublish
SO  - Arerugi. 2020;69(9):918-927. doi: 10.15036/arerugi.69.918.